Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 29:5:61-70.
doi: 10.4137/BIC.S9455.

Molecular profiling for breast cancer: a comprehensive review

Muaiad Kittaneh  1 , Alberto J Montero, Stefan Glück
Affiliations
Review

Molecular profiling for breast cancer: a comprehensive review

Muaiad Kittaneh et al. Biomark Cancer. .

Abstract

In recent years advances in molecular biology have launched disruptive innovations in breast cancer diagnostics and therapeutics. The advent of genomics has revolutionized our understanding of breast cancer as several different biologically and molecularly distinct diseases. This research has led to commercially available polymerase chain reaction (PCR) and microarray tests that have begun to fundamentally change the way medical oncologists quantify recurrence risk in early stage breast cancer patients. The Genomics era has altered the clinicopathologic paradigm of selecting patients for adjuvant cytotoxic chemotherapy. Sufficiently powered prospective studies are underway that may establish these molecular assays as elements of standard clinical practice in breast cancer treatment. In this article, we review the strengths and limitations of currently available breast cancer-specific molecular tests.

Keywords: MammaPrint; Oncotype DX; PAM50; early breast cancer; molecular profiling; prognostic and predictive tests.

PubMed Disclaimer

References

    1. Gribbin J, Dewis R. Early and Locally Advanced Breast Cancer: Diagnosis and Treatment. Appendix 1. Adjuvant! Online: review of evidence concerning its validity, and other considerations relating to its use in the NHS. http://www.ncbi.nlm.nih.gov/books/NBK11639/. Published February 2009.
    1. Gnant M, Steger GG. Fighting overtreatment in adjuvant breast cancer therapy. Lancet. 2009;374(9707):2029–2030. - PubMed
    1. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374:2055–2063. - PMC - PubMed
    1. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–10874. - PMC - PubMed
    1. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–8423. - PMC - PubMed